Abstract: Tasdemir C et al. RESEARCH ARTICLE Canatan Tasdemir1 Ertugrul Guclu2 Zeynep Devran3 El Medina Hotschka2 Yusuf Aydemir4 Aziz Ogutlu2 Oguz Karabay2 1 Sakarya University Training and Research Hospital, Department of Chest Diseases, Sakarya, Turkey 2 Sakarya University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Sakarya, Turkey 3 Sakarya Provincial Health Directorate, Sakarya, Turkey 4 Sakarya University Faculty of Medicine Department of Pulmonology, Sakarya, Turkey Famotidine in COVID-19 Treatment ABSTRACT Objective: Famotidine is an H2 receptor antagonist (H2RA) and has been shown to have antiviral properties in in vitro studies. Pantoprazole is one of the proton pump inhibitors (PPI). In this study, it was aimed to compare the efficacy of famotidine with pantoprazole in the treatment of COVID-19. Methods: Patients who were hospitalized and given famotidine and pantoprazole treatment for at least 48 hours were included in the study. Demographic, clinical and laboratory findings of the patients were analyzed retroprospectively from the patient files. The patients were divided into two groups as the famotidine group and the pantoprazole group. The groups were compared in terms of the need for intensive care and mortality rates. In addition, among the groups, the number of patients with normal oxygen saturation at discharge, number of days needed for oxygen support, number of days with fever, and length of hospital stay were evaluated. Results: A total of 179 Covid-19 patients (85 famotidine, 94 pantoprazole) were included in the study. Demographic findings and other symptoms except dyspnea were similar in both groups. Dyspnea, chronic diseases, and the number of patients given steroids were higher in those who were given pantoprazole (p<0.05). Mortality and ICU need were similar in both groups (respectively; p=0.25, p=0.26). The number of days with fever, duration of hospitalization, and the number of days requiring oxygen support were less in those given famotidine (respectively; p=0.04, p=0.003, p=0.014). Conclusions: Famotidine did not reduce the need for intensive care and mortality in COVID-19 patients treated in the hospital. New therapeutic agents are needed to reduce disease severity and mortality. Keywords: COVID-19, Famotidine, Pantoprazole, Mortality. Corresponding Author: Yusuf Aydemir Sakarya University Faculty of Medicine Department of Pulmonology, Sakarya, Turkey mail: dryaydemir@yahoo.com Phone: +90 5056369494 Received: 11.05.2021 Acceptance: 12.07.2021 DOI: 10.18521/ktd.935888 Konuralp Medical Journal e-ISSN1309–3878 konuralptipdergi@duzce.edu.tr konuralptipdergisi@gmail.com www.konuralptipdergi.duzce.edu.tr COVID-19 Tedavisinde Famotidin Kullanımı ÖZET Amaç: Famotidin, bir H2 reseptör antagonistidir ve in vitro çalışmalarda antiviral özelliklere sahip olduğu gösterilmiştir. Pantoprazol, proton pompası inhibitörlerinden biridir. Bu çalışmada, COVID19 tedavisinde Famotidinin ile Pantaprazolun etkinliğinin karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Çalışmaya en az 48 saat famotidin ve pantaprazol tedavisi verilen ve hastanede yatan hastalar dâhil edildi. Hastaların demografik, klinik ve laboratuvar bulguları hasta dosyalarından geriye dönük olarak incelendi. Hastalar famotidin grubu ve pantoprazol grubu olarak iki gruba ayrıldı. Gruplar yoğun bakım ihtiyacı ve ölüm oranları açısından karşılaştırıldı. Ayrıca gruplar arasında taburculukta oksijen saturasyonu normal olan hasta..